---
document_datetime: 2023-09-21 22:16:26
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fotivda-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: fotivda-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.0357386
conversion_datetime: 2025-12-23 03:11:42.221805
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fotivda

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|---------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IAIN/0026            | A.1-Administrative change-Change in the name and/oraddressof theMAH | 17/07/2023                          |                                            | SmPC, Labelling and PL          |           |
| IB/0024/G            | This was an applicationfor a group of variations.                   | 13/02/2023                          | n/a                                        |                                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.z-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-Other variation B.I.a.1.z-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS-Other variation   |            |            |                       |                                                                                                                                                                                                                                                                 |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0023             | B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved testprocedure                                                                                             | 17/01/2023 | n/a        |                       |                                                                                                                                                                                                                                                                 |
| PSUSA/10636 /202202 | PeriodicSafetyUpdateEUSingle assessment- tivozanib                                                                                                                                                                       | 29/09/2022 | n/a        |                       | PRACRecommendation-maintenance                                                                                                                                                                                                                                  |
| R/0021              | Renewalofthemarketing authorisation.                                                                                                                                                                                     | 19/05/2022 | 15/07/2022 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, theCHMPconsidered thatthebenefit-riskbalanceof Fotivda in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0020             | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                  | 14/10/2021 | n/a        |                       |                                                                                                                                                                                                                                                                 |
| IA/0019             | A.4-Administrative change-Change in the name and/or addressof amanufactureror anASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovel excipient         | 14/10/2021 | n/a        |                       |                                                                                                                                                                                                                                                                 |
| 11/0018             | Submissionof anupdatedRMPversion4.0 in order to include interim data from the phase III Study TIVO-3,a randomised,controlled,multi-centre,                                                                               | 30/09/2021 | n/a        |                       |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | open-labelstudytocomparetivozanibwithsorafenib insubjectswithadvancedRenal Cell Carcinoma. Addtional updatesto theRMPincludenew informationfromclinicalstudiesandpostmarketing exposure. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Implementation of change(s)whichrequire tobefurther substantiated bynewadditional data tobesubmittedby theMAH wheresignificantassessmentisrequired   |            |            |                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| PSUSA/10636 /202102 | PeriodicSafetyUpdateEUSingleassessment- tivozanib                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/09/2021 | n/a        |                        |
| IA/0017             | TochangetheATCCodeof tivozanibfromL01XE34 to L01EK03. A.6-Administrative change-Change in ATC Code/ATCVetCode                                                                                                                                                                                                                                                                                                                                                            | 01/06/2021 | 24/01/2022 | SmPC                   |
| IAIN/0015           | A.1 -Administrative change - Change in the name and/oraddressoftheMAH                                                                                                                                                                                                                                                                                                                                                                                                    | 26/01/2021 | 24/01/2022 | SmPC, Labelling and PL |
| PSUSA/10636 /202002 | PeriodicSafetyUpdateEUSingleassessment- tivozanib                                                                                                                                                                                                                                                                                                                                                                                                                        | 01/10/2020 | n/a        |                        |
| II/0012             | C.I.13-Othervariationsnotspecifically covered elsewherein thisAnnexwhichinvolve thesubmission of studies to thecompetent authority                                                                                                                                                                                                                                                                                                                                       | 17/09/2020 | n/a        |                        |

<div style=\"page-break-after: always\"></div>

| IB/0014/G           | This was an applicationfor a group ofvariations. B.I.a.2.z - Changes in the manufacturing process of the AS-Other variation B.I.a.3.b-Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.1.z-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-Other variation   | 03/08/2020   | n/a        |                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| PSUSA/10636 /201908 | PeriodicSafetyUpdateEUSingle assessment- tivozanib                                                                                                                                                                                                                                                                                                         | 12/03/2020   | n/a        |                 |
| IAIN/0010           | C.I.z-Changes(Safety/Efficacy)ofHuman and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                       | 31/10/2019   | 10/08/2020 | SmPC and PL     |
| IB/0009             | C.1.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMp-Othervariation                                                                                                                                                                                                                      | 05/10/2019   | n/a        |                 |
| PSUSA/10636 /201902 | PeriodicSafetyUpdateEUSingleassessment tivozanib                                                                                                                                                                                                                                                                                                           | 05/09/2019   | n/a        |                 |
| IAIN/0008           | B.II.b.1.b-Replacement or addition of a manufacturingsitefortheFp-Primarypackaging site                                                                                                                                                                                                                                                                    | 26/08/2019   | n/a        |                 |
| IAIN/0007/G         | Thiswas an applicationfor a group ofvariations.                                                                                                                                                                                                                                                                                                            | 26/08/2019   | 10/08/2020 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.a-Replacementoradditionofa manufacturing site for the FP - Secondary packaging site B.II.b.2.a-Change to importer,batch release arrangementsandqualitycontroltestingoftheFP- Replacement/additionofasitewherebatch control/testingtakesplace B.I1.b.2.c.2-Change to importer,batch release arrangements andqualitycontrol testingof theFp- Including batch control/testing   |            |            |                        |                                                                                                                                                                                                                                                          |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10636 /201808 | PeriodicSafetyUpdateEUSingle assessment- tivozanib                                                                                                                                                                                                                                                                                                                                    | 14/03/2019 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                                           |
| T/0005              | Transfer ofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                     | 20/12/2018 | 14/02/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                          |
| PSUSA/10636 /201802 | PeriodicSafetyUpdateEUSingleassessment- tivozanib                                                                                                                                                                                                                                                                                                                                     | 06/09/2018 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                                           |
| II/0002             | Updateofthesection5.2oftheSmPCwith additionalinformationontransporterproteinsbased on the results of an invitro interaction transporter study. The updated RMP version 2.0 was also submitted. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance                                                                              | 08/02/2018 | 14/02/2019 | SmPC                   | Invitrostudieshaveshownthattivozanibisneithera substrate norinhibitor of the transporterproteins MDR1(P- gP), OCT1, OATP1B1, OATP1B3 and BSEP. Furthermore, tivozanibwasnotaninvitroinhibitorofOAT1,OAT3， OCT2,MATE1andMATE2-KorsubstrateofMRP2and BCRP. |

<div style=\"page-break-after: always\"></div>

| 11/0001   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range   | 07/12/2017   | n/a   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|